Was hast du dir denn mit Cardium therapeutics für ein genauso komisches Teil wie Keryx an Land gezogen,hm ? Und mich gleich mal für den thread gesperrt,was ! Vielleicht meintest du ja instinktiv "Cardiome Pharma" und hast dich nur im Namen vertan ?
P.S. Ich habe einen Thread zu Cardiome eröffnet und bin investiert,schau doch bei Gelegenheit mal vorbei,ich sperre da jedenfalls niemanden ....
enttäuschend, aber keryx arbeitet natürlich an seinen produkten und will die zulassung. das geht nicht von jetzt auf gleich. es können nicht jeden tag news kommen. geduld. nutzt die kurse zum nachkaufen
----------- "Wenn die klügeren nachgeben, setzen sich die dümmeren durch"
Kennt ihr Forodesine ? Gleich gegen 3 verschiedene Krebs-Indikationen in Phase-3,selbes wikprinzip wie Perifosine. Obendrein gibts mit Peramivir noch den zukünftigen Schweinegrippen Impfstoff (Da 10 mal billiger und wirksamer als Tamiflu) noch obendrauf !
Keryx Biopharmaceuticals Receives Orphan Drug Designation for KRX-0401 (Perifosine) for the Treatment of Neuroblastoma
NEW YORK, July 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies.
Phase 1 data of perifosine in recurrent pediatric solid tumors, including neuroblastoma, was presented last month in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Investigators from the Memorial Sloan-Kettering Cancer Center concluded that perifosine was demonstrated to be safe and well tolerated in children with advanced solid tumors and that perifosine may have antitumor clinical activity as a single agent in neuroblastoma. Additionally, in a preclinical study recently published in the Journal of the National Cancer Institute, perifosine showed a statistically significant reduction in neuroblastoma cell survival, slowed or regressed tumor growth, and increased survival in mice bearing neuroblastoma tumors. A decreased level of activated Akt was also observed in perifosine-treated neuroblastoma cells and xenograft tumors.
Ron Bentsur, Chief Executive Officer of Keryx, commented, "The Orphan Drug designation is an important component of our development plan for perifosine in neuroblastoma, an indication where no FDA approved therapies currently exist." Mr. Bentsur continued, "We are currently exploring next steps for the development of perifosine in this indication which we hope, ultimately, could provide a new treatment option for children and infants suffering with neuroblastoma."
